Pull to refresh
Logo
Insilico Medicine

Insilico Medicine

Clinical-stage biotechnology company

Appears in 5 stories

Stories

The AI science rush

New Capabilities

Rentosertib, its AI-designed drug for idiopathic pulmonary fibrosis, appeared safe and effective in small human trials reported June 2026

Science magazine named large language models doing frontier science a runner-up breakthrough of 2025. Within weeks, the prediction became reality: OpenAI's GPT-5.2 solved previously unsolved ErdΕ‘s mathematics problems in 15 minutes, achieving 40% accuracy on expert-level mathematics that stumped earlier systems.

Updated 5 days ago

AI longevity discovery toolkit opens to researchers worldwide

New Capabilities

Developer and publisher of the toolkit

Insilico Medicine opened its aging-research AI toolkit to anyone on September 17, 2026. The Cell cover study released LongevityBench, a 17-task benchmark for aging biology, plus Longevity-LLMs, five compact open-source language models trained on multi-omics data (genomics, proteomics, and other biological layers).

Updated Sep 18

AI-designed IPF drug enters Phase III trial, a first for generative AI

New Capabilities

Developer of Rentosertib; sponsor of GENESIS-IPF-3

Insilico Medicine dosed the first patient this week in a Phase III trial of Rentosertib, a drug for the progressive lung disease idiopathic pulmonary fibrosis. It's the first medicine with both an AI-identified target and an AI-designed molecule to reach this stage of testing.

Updated Sep 11

Insilico Medicine releases AI models that beat dedicated drug-discovery software

New Capabilities

Publicly listed on the Hong Kong exchange; releasing frontier specialist AI models

Insilico Medicine released AI models Sept. 2 that it says outperform the dedicated software drug companies have used for years. The language-model specialists cover chemical synthesis, drug-safety prediction, and target-binding strength.

Updated Sep 4

AI transforms drug discovery from years to hours

New Capabilities

Lead clinical-stage AI drug developer; Phase III for rentosertib expected Q4 2026; signed $2.5 billion neuroimmune collaboration with SK Biopharmaceuticals in June 2026

In January 2026, Tsinghua University researchers published DrugCLIP in Science, a system that screened 500 million drug compounds against 10,000 human proteins in under 24 hours on eight GPUs. The approach is 10 million times faster than conventional molecular docking, and the results are public in GenomeScreenDB, covering roughly half the human genome.

Updated Jun 27